COMP <GO>
BMRN vs JNJ // FREE CASH FLOW YIELD
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BMRN 4
— JNJ 9
▲ FREE CASH FLOW YIELD LEADER: BMRN
LAST: $58.51 (+1.77%) • MKT CAP: $11.13B
fcf-yield
6.51%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
fcf-yield
2.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 67.90% | +9.80 | BMRN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 25.50% | -19.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 18.5x | +2.50 | JNJ | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 6.51% | 2.97% | +3.54 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | 34.70% | -22.00 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 28.50% | -17.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 6.00% | +6.90 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 5.59 | -0.02 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | BMRN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.5 | 60.4 | -5.83 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 23.0x | +3.80 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.13B | $662.49B | -$651.36B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | JNJ REV | BMRN GROSS % | JNJ GROSS % | BMRN FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $94.19B | 77.7% | 67.9% | $725.0M | $19.70B |
| FY 2024 | $2.85B | $88.82B | 79.7% | 69.1% | $487.4M | $19.84B |
| FY 2023 | $2.42B | $85.16B | 44.0% | 44.0% | $50.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
JNJ // BETA 1.08